REMIND stands for Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease, a clinical research program exploring a fascinating, and admittedly unconventional, hypothesis: could supermicrosurgery improve the brain’s waste clearance system and, in doing so, modify the course of Alzheimer’s disease?
When I first read about the project, I immediately thought of the old saying: “If all you have is a hammer, everything looks like a nail.“ Where did this crazy idea come from? Then I remembered another story. In 1927, the Nobel Prize in Medicine was awarded to the Austrian psychiatrist Julius Wagner-Jauregg, who treated neurosyphilis, then an incurable disease, by deliberately infecting patients with malaria. His reasoning was based on careful clinical observation: fever occasionally seemed to improve the disease. It sounds extraordinary today, but before penicillin, it became the first effective treatment for general paresis and ultimately earned him the Nobel Prize. History reminds us that bold hypotheses deserve careful testing.
The brain is unique in that it lacks a conventional lymphatic network within its parenchyma. Instead, metabolic waste is removed through the recently described glymphatic system and the meningeal lymphatic vessels, which drain cerebrospinal fluid and soluble metabolites toward the cervical lymphatic system. This clearance pathway has become one of the most active areas of neuroscience research.
One of the unresolved questions in Alzheimer’s disease is why proteins such as β-amyloid and tau progressively accumulate within the brain. Although their exact role remains debated, impaired clearance has emerged as one plausible mechanism. The REMIND project is based on a simple engineering concept: if the brain’s “drainage system” can be enhanced, perhaps the accumulation of pathological proteins can be reduced, slowing, or even preventing neurodegeneration. This remains a hypothesis.
What has changed is that the surgical component has become technically feasible: performing lymphatic or venous anastomoses on vessels measuring less than 1 mm is now increasingly standardized thanks to robot-assisted supermicrosurgery. Systems such as Symani® provide motion scaling, tremor filtration and enhanced precision, making procedures that were once reserved for a handful of exceptional microsurgeons reproducible by a larger number of trained surgeons.
The REMIND study is currently underway as an FDA-approved Early Feasibility Study, evaluating robotic-assisted lymphovenous bypass in patients with mild Alzheimer’s disease. The trial is registered on ClinicalTrials.gov under NCT07178210, with the primary objective of assessing the safety and feasibility of the procedure rather than demonstrating clinical efficacy.
Naturally, there are many reasons for skepticism. Lymphatic reconstruction has already demonstrated clear clinical benefit in the treatment of extremity lymphedema, where lymphaticovenous anastomoses can significantly improve lymphatic drainage. (eg. after breast cancer surgery). We will discuss that application in a future post.
The situation in Alzheimer’s disease is entirely different. Robust evidence that enhancing cervical lymphatic drainage modifies neurodegeneration is still lacking. Also for the opposite. We, Head&Neck surgeons, have spent decades performing comprehensive cervical lymph node dissections without obvious neurological consequences. The lymphatic system has remarkable redundancy and adaptive capacity, and subtle physiological changes may not become clinically apparent for years, or may only matter in specific pathological conditions.
Can optimizing lymphatic drainage alter the natural history of Alzheimer’s disease?
So, can optimizing lymphatic drainage alter the natural history of Alzheimer’s disease? We simply do not know. But the biological rationale is coherent, the technology now exists to test the hypothesis safely, and regulators, including the FDA through its Early Feasibility Study pathway, consider the concept sufficiently plausible to justify clinical investigation. That is how medical progress works.
Let’s see where the evidence leads.
J Granell. Aug 2, 2026
References
Jessen NA, Munk AS, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner’s Guide. Neurochem Res. 2015 Dec;40(12):2583-99. doi: 10.1007/s11064-015-1581-6.
One thought on “REMIND. Robotic super-microsurgery for Alheimer´s disease.”